Drug General Information (ID: DDIYFS3V98)
Drug Name			Irinotecan		Drug Info		Sacituzumab govitecan		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antineoplastics				Antineoplastics
Structure

Mechanism of Irinotecan-Sacituzumab govitecan Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Irinotecan				Sacituzumab govitecan
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Irinotecan and Sacituzumab govitecan

Recommended Action
Management		Sacituzumab govitecan should not be substituted for or used with other drugs containing irinotecan or the active metabolite SN-38.

References
1	Product Information. Trodelvy (sacituzumab govitecan). Immunomedics, Morris Plains, NJ.